written on 12.02.2014

BioNotebook: IPOs abound as Dicerna, Celladon launch; Puma seeks $115m; Omeros looks to Phase IIb


Already public Puma Biotechnology also plans to take advantage of investor enthusiasm for biotechnology stocks. The Los Angeles-based company filed documents with the US Securities and Exchange Commission (SEC) to support a sale of up to $115m worth of…